Targeting DPP9 attenuates podocyte injury by regulating NRF2 antioxidant signaling
Chenkai Cui, Shizhuo Wei, Jianpeng Zhang, Jing Xu, Shokhida Naimova, Yan Li, Haodong Wang, Yinhong Wang, Ruoyan Si, Linting Wei, Fuqian Lei, Xiaoyong Yu, Pengfei Liu, Rongguo Fu · 2026
Read Targeting DPP9 attenuates podocyte injury by regulating NRF2 antioxidant signaling by Chenkai Cui, Shizhuo Wei, Jianpeng Zhang, Jing Xu, Shokhida Naimova, Yan Li, Haodong Wang, Yinhong Wang, Ruoyan Si, Linting Wei, Fuqian Lei, Xiaoyong Yu, Pengfei Liu, Rongguo Fu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13627425.txt.
Description
Chenkai Cui and fifteen co-authors uncover in 2026 a guardian protein for the kidney's filter cells. Podocytes wrap the kidney's tiny filters, and their injury drives chronic kidney disease, with oxidative stress a main weapon. A diabetes drug, finerenone, protects kidneys, but exactly how was fuzzy.
The team found the protein DPP9 fades in injured podocytes from patients and mice. Restoring it switched on the NRF2 defense system and shielded the cells; removing it worsened harm. Finerenone raises DPP9 levels, which then frees NRF2 from its keeper protein. The chain explains part of the drug's benefit and names DPP9 as a drug target.
Catalog record
| CREATOR | Chenkai Cui, Shizhuo Wei, Jianpeng Zhang, Jing Xu, Shokhida Naimova, Yan Li, Haodong Wang, Yinhong Wang, Ruoyan Si, Linting Wei, Fuqian Lei, Xiaoyong Yu, Pengfei Liu, Rongguo Fu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 47 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |